When was Cellect Biotechnology founded?

Cellect Biotechnology was founded in 2011 and raised its 1st funding round 6 years after it was founded.

Where is Cellect Biotechnology located?

Cellect Biotechnology is headquartered in Kfar Saba, Israel.

Who is the current CEO of Cellect Biotechnology?

Shai Yarkoni of Cellect Biotechnology. They have also founded 1 company.

How many employees does Cellect Biotechnology have?

As of Jun 30, 2026, the latest employee count at Cellect Biotechnology is 1.

Is Cellect Biotechnology a funded company?

Cellect Biotechnology is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Sep 11, 2017.

When was the latest funding round of Cellect Biotechnology?

Cellect Biotechnology's latest funding was a $***** Series A round on Sep 11, 2017, with participation from 0 investor. Its primary sector is Cell Therapy. Globally, the Cell Therapy sector has seen $643M in funding in 2026 to date.

Where does Cellect Biotechnology rank among its competitors?

Cellect Biotechnology ranks 36th amongst 53 active competitors, of which 17 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was HemoGenyx, which secured $3.41M in Feb, 2026.

Who are the top competitors of Cellect Biotechnology?

Cellect Biotechnology's top competitors include MaaT Pharma, Jasper Therapeutics and HemoGenyx. Among them, HemoGenyx secured the most recent funding round in February, 2026.

Cellect Biotechnology - 2026 Company Profile, Team, Funding & Competitors

Company Details

Cellect Biotechnology is a clinical stage company developing technology which enables the functional selection of stem cells based on their sensitivity to apoptosis. US FDA has granted orphan drug designation for its product, ApoGraft, for the prevention of acute and chronic graft versus host disease(GvHD) in transplant patients, in September 2017. ApoGraft is applicable to a wide variety of stem cell related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations.

Website: cellect.co
Social
Phone Number: +972 **********

Key Metrics

Founded Year

2011

Location

Kfar Saba, Israel

Stage

Public

Total Funding

$4.3M in 1 round

Latest Funding Round

Series A, Sep 11, 2017, $*****

Investors

Ilan Holdings

Ranked

36^th among 53 active competitors

Employee Count

1 as on Jun 30, 2026

Similar Companies

MaaT Pharma & 60 more

Exit Details

Public

View Cellect Biotechnology's full profile

Cellect Biotechnology got listed on Jul 29, 2016.

Click here to take a look at Cellect Biotechnology's IPO in detail

Cellect Biotechnology has raised a total funding of $4.3M over 1 round. Cellect Biotechnology has 1 institutional investor.

Here is the list of recent funding rounds of Cellect Biotechnology:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 11, 2017	1139833	Series A	9892078	4165074	8973278	3095917

Access funding benchmarks and valuations. Sign up today!

View details of Cellect Biotechnology's funding rounds and investors

The founders of Cellect Biotechnology are Shai Yarkoni and Nadir Ashkenazy. Shai Yarkoni is the CEO of Cellect Biotechnology.

Here are the details of Cellect Biotechnology's key team members:

Shai Yarkoni: Co-Founder & CEO of Cellect Biotechnology.
Nadir Ashkenazy: Co-Founder & CFO of Cellect Biotechnology.

View details of Cellect Biotechnology's Founder profiles and Board Members

Cellect Biotechnology's employee count trend

Cellect Biotechnology has 1 employees as of Jun 26. Here is Cellect Biotechnology's employee count trend over the years:

Employee count trend for Cellect Biotechnology

Uncover Cellect Biotechnology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellect Biotechnology include MaaT Pharma, Jasper Therapeutics and HemoGenyx. Here is the list of Top 10 competitors of Cellect Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Bpifrance, Symbiosis & 11 others	61/100
2nd	Jasper Therapeutics 1999, Redwood City (United States), Series A	Developer of therapeutics for chronic diseases by targeting mast cells and stem cells	$50M	Abingworth, Qiming & 5 others	62/100
3rd	HemoGenyx 2014, Buffalo (United States), Public	Developer of cell and gene therapies to treat blood diseases and viral infections	-	Design Technologies, 43North & 3 others	62/100
4th	GigaGen 2011, San Francisco (United States), Acquired	Developer of T-cell and antibody-based therapeutics	$36.1M	Claremont Creek Ventures, Sequoia Capital ... & 5 others	59/100
5th	Lipella 2005, Pittsburgh (United States), Public	Developer of lipid-based therapies for common bladder syndromes	$3.37M	HHS, Military Health	57/100
6th	Priothera 2020, Dublin (Ireland), Series A	Developer of therapeutics for the treatment of hematological malignancies	$35.5M	Fountain Healthcare Partners, Healthcap & 4 others	47/100
7th	Veloxis 2002, Edison (United States), Acquired	Transforming transplant medicine through innovative therapies and programs for healthcare providers	-	Lundbeck Foundation, Athyrium Capital Management ... & 4 others	47/100
8th	Xenikos 2009, Nijmegen (Netherlands), Series C	Developer of toxin-loaded antibodies for T-cell mediated diseases	$82M	RA Capital Management, Medicxi & 6 others	47/100
9th	ActiTrexx 2020, Mainz (Germany), Series A	Provider and developer of cellular therapy agents for stem cell transplantation patients	$4.22M	LBBW Venture Capital, HTGF & 5 others	47/100
10th	BioCardia 2002, San Carlos (United States), Public	Clinical-stage cardio regenerative medicine company with an initial focus on heart failure.	-	Thoratec, Maryland Stem Cell Research Fund ... & 1 others	46/100
36th	Cellect Biotechnology 2011, Kfar Saba (Israel), Public	Developer of stem cells selection technology, ApoGraft	$4.3M	Ilan Holdings	31/100